Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI

Cancer Biology and Medicine

Volumn 11, Issue 4, 2014, Pages 270-276

  Xia, Guo Hao ^a   Zeng, Yun ^a   Fang, Ying ^a   Yu, Shao Rong ^a   Wang, Li ^a   Shi, Mei Qi ^a   Sun, Wei Li ^a   Huang, Xin En ^a   Chen, Jia ^a   Feng, Ji Feng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Acquired resistance; Chemotherapy; Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI); Erlotinib; Gefitinib; Non small cell lung cancer (NSCLC)

Indexed keywords

ALBUMIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NEDAPLATIN; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RASH; RETREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84921971275     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.04.006     Document Type: Article

References (21)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
4. Tomizawa Y, Fujita Y, Tamura A, Shirai M, Shibata S, Kawabata T, et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 2010;68:269-272.
5. Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 2011;74:268-273.
6. An T, Huang Z, Wang Y, Wang Z, Bai H, Wang J. Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011;14:261-265.
7. Zhang ZJ, Zhang P, Wu XN, Li L, Cheng G. Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010;32:371-374.
8. Song ZB, Yu YF, Chen ZW, Lu S. Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chin Med J (Engl) 2011;124:2279-2283.
9. Saito H, Murakami S, Kondo T, Oshita F, Noda K, Yamada K, et al. Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. Onkologie 2012;35:18-22.
10. Oh IJ, Ban HJ, Kim KS, Kim YC. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 2012;77:121-127.
11. Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, et al. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer 2013;82:299-304.
12. Tomizawa Y, Fujita Y, Tamura A, Shirai M, Shibata S, Kawabata T, et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 2010;68:269-272.
13. Sun Y, Shi YK. eds. Reasonable medication Manual of Clinical Oncology (Fifth edition). Beijing: People's Medical Publishing House, 1997;49-51.
14. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155.
15. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
16. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005;11:1572-1578.
17. Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer 2008;123:2939-2949.
18. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11:7480-7489.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
20. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-2533.
21. Tang C, Li X, Guo W, Li J, Qin H, Wang W, et al. How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI? Zhongguo Fei Ai Za Zhi 2013;16:345-352.